Mouse models of myelodysplastic syndromes.
Three general approaches have been used to model myelodysplastic syndrome (MDS) in mice, including treatment with mutagens or carcinogens, xenotransplantation of human MDS cells, and genetic engineering of mouse hematopoietic cells. This article discusses the phenotypes observed in available mouse models for MDS with a concentration on a model that leads to aberrant expression of conserved homeobox genes that are important regulators of normal hematopoiesis. Using these models of MDS should allow a more complete understanding of the disease process and provide a platform for preclinical testing of therapeutic approaches.
Beachy
Sarah H
SH
Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 8901 Wisconsin Avenue, Bethesda, MD 20889-5105, USA.
Aplan
Peter D
PD
D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D004268:DNA-Binding Proteins / Q000235:genetics; D004195:Disease Models, Animal; D005786:Gene Expression Regulation; D055879:Gene Knock-In Techniques; D005801:Genes, Homeobox; D016147:Genes, Tumor Suppressor; D006410:Hematopoiesis / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D051379:Mice; D016688:Mice, Inbred NOD; D018345:Mice, Knockout; D016513:Mice, SCID; D008822:Mice, Transgenic; D009153:Mutagens / Q000633:toxicity; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000235:genetics / Q000473:pathology; D022423:Myeloid Cells / Q000473:pathology; D011519:Proto-Oncogenes; D013045:Species Specificity; D014183:Transplantation, Heterologous
D002273:Carcinogens; D004268:DNA-Binding Proteins; D009153:Mutagens